scispace - formally typeset
L

Leif Bertilsson

Researcher at Karolinska University Hospital

Publications -  321
Citations -  24620

Leif Bertilsson is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Debrisoquine & Debrisoquin. The author has an hindex of 87, co-authored 321 publications receiving 23933 citations. Previous affiliations of Leif Bertilsson include Astra & University of Oulu.

Papers
More filters
Journal ArticleDOI

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.

Adrián LLerena, +4 more
- 01 Apr 1992 - 
TL;DR: PM of debrisoquine (7% of Caucasian populations) might, therefore, on common doses of haloperidol, achieve high plasma concentrations and thereby have an increased risk of side effects and at the other extreme, very rapid metabolizers may need increased doses of Haloperidols.
Journal ArticleDOI

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.

Chiaki Kawanishi, +4 more
- 01 Jan 2004 - 
TL;DR: The results suggest that the CYP2D6 gene duplication is a possible factor that influences the development of persistence in patients with mood disorders probably by ultrarapid drug metabolism.
Journal ArticleDOI

Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.

Leif Bertilsson, +3 more
- 01 Jan 1985 - 
Journal ArticleDOI

Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.

Adrián LLerena, +5 more
- 01 Jan 1993 - 
TL;DR: There may be a relationship between personality and the activity of the enzyme hydroxylating debrisoquine (cytochrome P4502D6), which may have an endogenous neuroactive substrate or product, such as a biogenic neurotransmitter amine.
Journal ArticleDOI

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.

Magnus Christensen, +19 more
- 01 Jun 2003 - 
TL;DR: Whether the drugs caffeine, losartan, omeprazole, debrisoquin (INN, debrisoquine), and quinine can be given simultaneously in low doses as a cocktail for the phenotyping of cytochrome P450 (CYP) 1A2, 2C9,2C19, 2D6, and 3A4 is determined.